Stock Traders Purchase High Volume of Merck & Co Call Options (MRK)
Merck & Co (NYSE:MRK) saw unusually large options trading on Tuesday. Stock investors purchased 35,883 call options on the stock, American Banking News.com reports. This is an increase of approximately 148% compared to the typical daily volume of 14,476 call options.
A number of analysts have recently weighed in on MRK shares. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co in a research note to investors on Tuesday. They now have a $48.00 price target on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Sunday. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Friday, October 18th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $50.76.
Shares of Merck & Co (NYSE:MRK) traded up 0.51% on Tuesday, hitting $45.58. 15,889,954 shares of the company’s stock traded hands. Merck & Co has a 52-week low of $40.02 and a 52-week high of $50.16. The stock has a 50-day moving average of $47.92 and a 200-day moving average of $46.68. The company has a market cap of $133.4 billion and a price-to-earnings ratio of 27.16.
Merck & Co (NYSE:MRK) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.92 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.88 by $0.04. The company had revenue of $11.03 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. The company’s quarterly revenue was down 4.0% on a year-over-year basis. On average, analysts predict that Merck & Co will post $3.47 earnings per share for the current fiscal year.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.